View Post

Germline-Targeting HIV Vaccine Candidate Prepares Phase 1 Study

In COVID-19, Latest News by Precision Vaccinations

After nine years of refinement at Fred Hutchinson Cancer Center in Seattle, a different kind of HIV vaccine candidate is nearing its first testing in human volunteers.
This innovative HIV vaccine is intended to train a person’s immune system to mount a robust antibody response against the virus that causes AIDS.
The HVTN 301 phase 1 clinical trial is among the first studies to try out this next-generation vaccine concept known as germline targeting. 

View Post

Wild Polio Continues Paralyzing Children in Pakistan

In Travel Vaccine News by Travel Vaccine

To eradicate polio, the Global Polio Eradication Initiative has brought together the latest scientific knowledge on poliovirus to make the most of lessons learned and plan for a world without polio.
While most of the world seldom confirms a polio case, Afghanistan and Pakistan are two countries that continue to battle this vaccine-preventable disease.
To prevent poliovirus from spreading across borders, Pakistan and Afghanistan synchronized nationwide polio immunization campaigns in May 2022.

View Post

1,200 Monkeypox Close-Contacts Vaccinated

In COVID-19, Latest News by Precision Vaccinations

According to media reporting yesterday, the number of people in eleven U.S. states who have received a monkeypox virus (MPX) preventive vaccine has reached about 1,200.
CNN reported White House senior director for global health security and biodefense (Dr. Raj Panjabi) stated on June 3, 2022, "We want to ensure that people with high-risk exposures have rapid access to vaccines."
“And 100 treatment courses (sent) to eight jurisdictions, and we have more to offer states."

View Post

North Carolina Vaccine Facility Certified for the Next Pandemic

In COVID-19, Latest News by Precision Vaccinations

If the U.S. government declares an influenza pandemic, a new vaccine production facility located in Holly Springs, North Carolina, is certified and ready to go.
New Jersey-based Seqirus announced today that the company's innovative manufacturing facility has successfully achieved all criteria required to establish domestic manufacturing capability for cell-based seasonal and pandemic influenza vaccines as outlined by the Biomedical Advanced Research and Development Authority (BARDA).